AVEO Oncology announced the appointment of Scarlett Spring to its Board of Directors, effective November 18, 2019. In accordance with the company's second amended and restated By-Laws, Ms. Spring will serve as a director until the 2020 Annual Meeting of Stockholders (the 2020 Annual Meeting) and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries. Ms. Spring currently serves as Co-Founder and Chief Executive Officer of TapRoot Interventions & Solutions. She previously served as President and Chief Commercial Officer for VisionGate, Inc. Prior to VisionGate, Ms. Spring served in various sales and commercial roles of increasing responsibility at Merck and AstraZeneca Pharmaceuticals.